Seagen Inc (NASDAQ:SGEN)

175.72
Delayed Data
As of 4:00pm ET
 -2.61 / -1.46%
Today’s Change
105.43
Today|||52-Week Range
192.79
+13.66%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$36.9B

Company Description

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Contact Information

Seagen Inc.
21823 30th Drive SE
Bothell Washington 98021
P:(425) 527-4000
Investor Relations:
(425) 527-4160

Employees

Shareholders

Mutual fund holders47.96%
Other institutional42.99%
Individual stakeholders26.56%

Top Executives

Roger D. DanseyChief Executive & Medical Officer
Todd E. SimpsonChief Financial Officer
Vaughn B. HimesChief Technical Officer
Natasha A. HerndayExecutive Vice President-Corporate Development
Dennis BenjaminSenior Vice President-Translational Research